Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 USD | -3.49% | -.--% | +3.75% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Chart calendar Reneo Pharmaceuticals, Inc.
Upcoming events on Reneo Pharmaceuticals, Inc.
Past events on Reneo Pharmaceuticals, Inc.
2024-05-07 07:35 am | Q1 2024 Earnings Release |
2024-03-28 07:35 am | Q4 2023 Earnings Release |
2023-11-13 07:35 am | Q3 2023 Earnings Release |
2023-11-06 05:30 pm | Translational Research in Mitochondria Metabolism Aging and Disease Meeting |
2023-10-25 02:00 pm | PittGene Meeting |
2023-10-10 | Jefferies Inaugural Biotech CNS/Neuro Summit |
2023-10-09 12:00 pm | Investor Meeting - Key Opinion Leader |
2023-09-27 09:00 am | Cantor Global Healthcare Conference |
2023-09-20 11:00 am | Leerink Partners Biopharma Summit |
2023-09-12 09:00 am | Baird Global Healthcare Conference |
2023-09-06 09:00 am | Citi BioPharma Conference |
2023-08-10 07:35 am | Q2 2023 Earnings Release |
2023-07-10 | SVB Securities Therapeutics Forum |
2023-06-30 11:30 am | UMDF Mitochondrial Medicine Symposium - Platform Session 5 |
2023-06-29 05:45 pm | UMDF Mitochondrial Medicine Symposium - PPAR? Agonist Mavodelpar (REN001) |
2023-06-29 05:45 pm | UMDF Mitochondrial Medicine Symposium - Clinical Manifestations and Disease Burden |
2023-06-28 05:30 pm | UMDF Mitochondrial Medicine Symposium - Clinical Manifestations |
2023-06-28 05:30 pm | UMDF Mitochondrial Medicine Symposium - Mavodelpar Clinical Development |
2023-06-10 | Euromit Bologna Conference |
2023-06-07 11:00 am | Jefferies Global Healthcare Conference |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBITDA | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | 0,00 | -39,8 -43,2 7.87% | -53,8 -54,0 0.2% | -83,1 -78,8 -5.43% | -25,8 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -39,8 -43,3 8.14% | -52,0 -52,8 1.66% | -77,4 -74,7 -3.6% | -22,0 |
Net income Million USD | Released Forecast Spread | -19,5 | -39,8 -43,2 7.84% | -52,0 -53,0 1.89% | -77,4 -73,4 -5.41% | -22,0 |
EPS USD | Released Forecast Spread | -9,58 | -2,19 -3,23 32.27% | -2,12 -2,16 1.62% | -2,52 -2,36 -7.01% | -0,65 |
Announcement Date | 19/03/21 | 23/03/22 | 27/03/23 | 28/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 |
EBIT Million USD | Released Forecast Spread | -13,0 -12,9 -0.8% | -12,4 -14,1 12.02% | -13,8 -13,6 -2.06% | -14,6 -14,7 0.73% | -16,1 -15,2 -6.27% | -21,0 -16,3 -28.75% | -20,9 -20,9 0.22% | -25,0 -20,7 -20.67% | -9,56 -17,0 43.75% | -4,25 | -3,25 | -3,25 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,0 -12,7 -2.61% | -12,3 -14,1 12.74% | -13,0 -14,0 7.31% | -13,6 -14,5 5.91% | -15,1 -14,9 -1.43% | -19,5 -16,3 -19.96% | -19,2 -21,0 8.37% | -23,6 -20,9 -12.82% | -8,43 -15,0 43.86% | -3,33 | -2,35 | -2,36 |
Net income Million USD | Released Forecast Spread | -13,0 -12,8 -2.01% | -12,3 -14,1 12.74% | -13,0 -13,5 3.78% | -13,6 -14,6 6.7% | -15,1 -14,8 -1.83% | -19,5 -16,1 -21.5% | -19,2 -20,2 4.99% | -23,6 -19,6 -20.4% | -8,43 -15,8 46.73% | -3,33 | -2,35 | -2,36 |
EPS USD | Released Forecast Spread | -0,53 -0,52 -1.92% | -0,50 -0,57 12.28% | -0,53 -0,55 3.05% | -0,55 -0,59 6.38% | -0,60 -0,60 0.66% | -0,65 -0,49 -32.65% | -0,57 -0,61 7.17% | -0,71 -0,57 -24.56% | -0,25 -0,43 42.31% | -0,10 | -0,07 | -0,07 |
Announcement Date | 10/05/22 | 09/08/22 | 08/11/22 | 27/03/23 | 11/05/23 | 10/08/23 | 13/11/23 | 28/03/24 | 07/05/24 | - | - | - |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
2024-07-25 01:00 am | BACHEM HOLDING AG: Q2 2024 Earnings Release |
2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
2024-07-26 01:00 am | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Reneo Pharmaceuticals, Inc.
2024-05-29 04:01 pm | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
2024-05-23 07:00 am | CUREVAC N.V.: Q1 2024 Earnings Release |
2024-05-22 01:00 am | EVOTEC SE: Q1 2024 Earnings Release |
2024-05-21 05:14 pm | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | KYVERNA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RPHM Stock
- Calendar Reneo Pharmaceuticals, Inc.